BiotechTube
Frontier Biologics

Frontier Biologics

Cambridge, United States· Est.
frontierbiologics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3M

Overview

Founded in 2020 and headquartered in Waco, Texas, Frontier Biologics is a private, pre-revenue biotech focused on regenerative medicine. The company's core asset is its Evexcell™ processing platform, which gently processes donated birth tissues to produce acellular biologic therapies. With a state-of-the-art cGMP facility and an initial IND submission targeted for Q1 2023, Frontier aims to establish itself in the growing regenerative medicine market by prioritizing product safety, efficacy, and regulatory compliance.

Regenerative Medicine

Technology Platform

Proprietary Evexcell™ processing platform for gentle, additive-free preparation of acellular biologics from perinatal tissues, emphasizing preservation of extracellular vesicles (exosomes), proteins, and growth factors. Utilizes advanced nanoparticle characterization (Stokes-Einstein equation) for quality control.

Funding History

1
Total raised:$3M
Seed$3M

Opportunities

The global regenerative medicine market offers significant growth potential, particularly for standardized, off-the-shelf biologic products.
Frontier's focus on extracellular vesicle preservation aligns with cutting-edge research, potentially offering efficacy advantages in wound healing and anti-inflammatory applications.
Strategic partnerships with larger biotech or medtech firms could accelerate development and market access.

Risk Factors

High clinical development risk as the company has not yet initiated trials.
Faces intense competition in the perinatal tissue biologics market from numerous established and emerging players.
Regulatory pathways for complex, acellular EV-rich products are not fully standardized, posing approval challenges.

Competitive Landscape

Frontier operates in the crowded space of perinatal tissue-derived biologics, competing with public companies like Organogenesis (NuCel) and MiMedx, as well as many private firms. Its key claimed differentiator is its gentle, proprietary processing method focused on EV integrity, competing against products that may use harsher processing techniques. Success hinges on proving clinical superiority or a unique mechanism of action.

More companies in Biologics / Biosimilars →More companies in United States →